摘要
目的:探讨熊去氧胆酸预防ERCP术后胆石复发的临床疗效及机制。方法:选取2011年3月-2013年5月本院收治的胆总管结石患者100例作为研究对象,随机分为对照组和治疗组,每组50例。所有患者均行ERCP取石术,对照组术后不给予任何处理,治疗组给予熊去氧胆酸胶囊500 mg/d口服,连服24个月。观察并比较两组患者临床症状、肝功能及结石复发情况。结果:治疗组手术后胆石症状均较手术前改善,且术后2年右上腹不适、黄疸及发热症状均低于对照组,比较差异均有统计学意义(P<0.05);治疗组术后第3周肝功能指标优于对照组,比较差异有统计学意义(P<0.05);治疗组胆石复发率为6.00%,低于对照组的22.00%,比较差异有统计学意义(P<0.05)。结论:熊去氧胆酸胶囊对预防ERCP术后胆石症复发有很好的疗效,还可促进患者肝功能的恢复及改善临床症状。
Objective： To investigate the clinical curative effect and mechanism of Ursodeoxycholic Acid （ UDCA ） to prevent the recurrence of gallstones after ERCP.Method： From March 2011 to May 2013, 100 cases of common bile duct stones in our hospital were selected as the research objects, they were randomly divided into the control group and treatment group, each group had 50 eases.ERCP was performed in all patients, the control group was riot given any treatment and the treaiment group was given 500 mg/d oral Ursodeoxycholie acid for 24 months, the clinical symptoms, liver function and stone recurrence of the two groups were observed and compared.Result ： The symptoms of gallstone in the treatment group were better than before operation, the right upper abdominal discomfort, jaundice and fever symptoms in postoperative 2 years were lower than that of the control group, the differences were statistically significant （ P〈0.05 ） .The liver function indexs of the treatment group were better than that of the control group after operation 3 weeks, the difference was statistically significant （ P〈0.05 ） .The recurrence rate of gallstone in the treatment group was 6.00%, which was lower than 22.00% of the control group, the difference was statistically significant （P〈0.05） .Conclusion： UDCA capsule has obvious effect on recurrence prevention of eholedoehal calculi, it can significantly recover liver function and improve clinical symptoms.
出处
《中国医学创新》
CAS
2016年第28期23-26,共4页
Medical Innovation of China
关键词
ERCP术
胆石症
熊去氧胆酸
Endoscopic retrograde cholangiopancreatography
Cholelithiasis
Ursodeoxycholie acid
